Marc Tessier-Lavigne - Jan 3, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: Director
Signature: /s/**Marc Trevor Tessier-Lavigne
Stock symbol: REGN
Transactions as of: Jan 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/5/2022, 03:23 PM
Previous filing: Feb 17, 2022
Next filing: Mar 18, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Award	$0	+191	+9.19%	$0.00	2.27K	Jan 3, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Award	$0	+2.71K		$0.00	2.71K	Jan 3, 2022	Common Stock	2.71K	$625.60	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2	On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.